RepliCel Life Sciences Inc (OTCQB:REPCF)

0.287
Delayed Data
As of Apr 19
 -0.013 / -4.33%
Today’s Change
0.26
Today|||52-Week Range
0.78
-7.42%
Year-to-Date
SECTOR
Non-Energy Minerals
INDUSTRY
Precious Metals
MARKET CAP
$6.4M

Company Description

RepliCel Life Sciences, Inc. is regenerative medicine company. It focuses on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. The firm's products include RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company was founded on April 24, 1967 and is headquartered in Vancouver, Canada.

Contact Information

RepliCel Life Sciences, Inc.
570 Granville Street
Vancouver British Columbia V6C 3P1
P:(604) 248-8730
Investor Relations:
(604) 248-8693

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Robert Lee BucklerPresident, Chief Executive Officer & Director
Thomas Albert KordybackChief Financial Officer
Rolf HoffmannChief Medical Officer
Kevin McElweeChief Scientific Officer
Hisae NakamuraDirector-Research & Development